Effect of iron chelation therapy on EPO-Stat5 signaling pathway and Treg expression in IPSS low risk/ medium risk-1 group myelodysplastic syndrome patients
2Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93:741-752.
3Bennett JM, MDS Foundation' s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodys- plastic syndromes. Am J Hematol, 2008, 83:858-861.
4Wells RA, Leber B, Buckstein R, et al. Iron overload in myelo- dysplastic syndromes:a Canadian consensus guideline. Leuk IRes, 2008, 32 : 1338-1353.
5Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med, 2009, 60:25-38.
6Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diag- nosis and management of aplastic anaemia. Br J Haematol, 2009, 147 :43-70.
7Tefferi A, Vardiman JW. Myelodysplastic syndromes [J]. N Eng J Med, 2009, 361:1872-1885. doi: 10.1056/NEJMra0902908.
8Gattermann N, Rachmilewitz EA. Iron overload in MDS- pathophysiology, diagnosis, and complications [J]. Ann Hematol, 2011, 90(1):1-10. doi: 10.1007/s00277-010-1091-1.
9Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells IJ]. Cytometry A, 2008, 73 ( 1 ):22-27. doi: 10.1002/cyto.a.20491.
10Bresgen N, Eckl PM. Oxidative stress and the homeodynamics of iron metabolism [ J ]. Biomoecules, 2015, 5 ( 2 ) :808 - 847. doi: 10.3390/biota5020808.
